Tepotinib vs Vebreltinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline
Tepotinib · Tepmetko
Marketed by Merck KGaA and partners
NCT02864992 · Phase 2 · active, not recruiting
The study was open-label and had no randomized comparator arm, so the reported tumor responses cannot be distinguished from outcomes that might have occurred with other treatment or without tepotinib. Although response was assessed by an independent review committee and results were reported for 337 participants, the primary endpoint was descriptive in this single-arm design.
Next expected readout: December 2027 · NCT06083857 (registry estimate)
Reported efficacy
Objective response rate (ORR) by independent review committee (IRC): ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months (not_applicable)
Result source: NCT02864992
Vebreltinib
Marketed by Avistone Biotechnology under a licence from Apollomics Inc.
NCT04258033 · Phase 2 · completed
This is an open-label, single-arm study with no randomization and no comparator group. The response rate in cohort 1 was high and its confidence interval cleared a preset benchmark, but without a control group the size of the drug's effect cannot be judged directly.
Next expected readout: December 2026 · NCT06343064 (registry estimate)
Reported efficacy
Objective response rate (2 years): Primary endpoint objective response rate 75% (95% CI, 61.1 to 86) per blinded independent review committee (met)
Result source: NCT04258033
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Tepotinib | Vebreltinib |
|---|---|---|
| PFS, median | 4.9 vs 4.4vs Pemetrexed and Cisplatin/CarboplatinNCT019829551 other result
| —Trial running · NCT06970782 |
| OS, median | 17.3 vs 19.5vs Pemetrexed and Cisplatin/CarboplatinNCT01982955 | —Trial running · NCT06970782 |
| ORR | 45.2% vs 33.3%vs Pemetrexed and Cisplatin/CarboplatinNCT019829552 other results
| —Trial running · NCT06970782 |
| Duration of response, median | —Trial running · NCT06908993 | —Trial running · NCT06970782 |
PFS, median
- Tepotinib
- 4.9 vs 4.4vs Pemetrexed and Cisplatin/CarboplatinNCT01982955
1 other result
- 10.2 vs 4.3 NCT01982955
- Vebreltinib
- —Trial running · NCT06970782
OS, median
- Tepotinib
- 17.3 vs 19.5vs Pemetrexed and Cisplatin/CarboplatinNCT01982955
- Vebreltinib
- —Trial running · NCT06970782
ORR
- Tepotinib
- 45.2% vs 33.3%vs Pemetrexed and Cisplatin/CarboplatinNCT01982955
2 other results
- 33.3% NCT01982955
- 33.3% NCT01982955
- Vebreltinib
- —Trial running · NCT06970782
Duration of response, median
- Tepotinib
- —Trial running · NCT06908993
- Vebreltinib
- —Trial running · NCT06970782
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Tepotinib: 3 of 4 rows · Vebreltinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tepotinib |
|---|---|
| Dropout rate | 0%500 mg + 250 mga NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results0%500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 0%300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —500 mg + 250 mga NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results—500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination —300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 58.3%500 mg + 250 mga NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results41.9%500 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 66.7%300 mg + 250 mg NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 500 mg + 250 mga diarrhoea 83.3% dyspnoea exertional 41.7% fatigue 41.7% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination show 2 more results500 mg + 250 mg diarrhoea 58.1% oedema peripheral 38.7% amylase increased 35.5% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination 300 mg + 250 mg amylase increased 66.7% diarrhoea 66.7% blood alkaline phosphatase increased 50% NCT01982955 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tepotinib
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tepotinib's landscape · Vebreltinib's landscape